gms | German Medical Science

10th Munich Vascular Conference

01.-03.12.2021, online

Infra-inguinal bypass graft surveillance is an opportunity to optimise statin and antiplatelet therapy to reduce 12-month major amputation and mortality rates

Meeting Abstract

10th Munich Vascular Conference. sine loco [digital], 01.-03.12.2021. Düsseldorf: German Medical Science GMS Publishing House; 2021. Doc05

doi: 10.3205/21mac05, urn:nbn:de:0183-21mac052

Veröffentlicht: 22. Dezember 2021

© 2021 Laloo et al.
Dieser Artikel ist ein Open-Access-Artikel und steht unter den Lizenzbedingungen der Creative Commons Attribution 4.0 License (Namensnennung). Lizenz-Angaben siehe



Background: Infra-inguinal bypass graft failure within the first two postoperative years can result from stenotic lesions within the conduit and near the anastomosis [1]. Despite limited prospective data, the Global Vascular Guidelines (2019) recommends regular clinical assessment and duplex ultrasound (DUS) [1]. NICE guidance (2020) recommends offering high-intensity statin and antiplatelet therapy to patients post-revascularisation [2]. This study aims to assess the graft surveillance uptake, patency, amputation and death rates among infra-inguinal bypass surgery patients at 1, 6 and 12 months postoperatively.

Methods: Patients undergoing infra-inguinal bypass at a single vascular centre between 1st January 2018 and 31st December 2019 were identified from the prospectively collected database and Caldicott-approved data collection was performed with 1 year follow-up as per local protocol. The primary outcomes at 1, 6 and 12 months postoperatively included: graft DUS surveillance uptake, patency, major amputations and death rates. Statins, LDL Cholesterol (LDL-C) levels and antiplatelet therapy were recorded at time of operation (baseline) and 1 year post-operatively. Statistical analysis with SPSS® was performed using chi-squared tests and paired sample t-tests to compare means (p<0.05 defined as significant).

Results: Of the 91 patients included in this study, 79.1% were men and median age was 71 years (IQR 62-76). Femoral-popliteal bypass was the most commonly performed infra-inguinal bypass (61.5%). At 1, 6 and 12 months, DUS surveillance uptake was 74.2%, 77.5% and 73.3% respectively while primary-assisted patency rates were 88.2%, 78.8% and 65.3% respectively and secondary patency rates were 97.6%, 96.3% and 96.3% respectively. Major amputation rates at 1, 6 and 12 months were 5.4%, 8.6%, 8.6% respectively. Death rates at 1, 6 and 12 months were 3.2%, 5.4% and 10.8% respectively. Proportion of patients on high-intensity statin increased from 71.4% at baseline to 77.9% at 1 year (p<0.001). Mean (SD) LDL-C level remained unchanged at baseline and 1 year at 1.75 (0.86) mmol (p=0.929). Patients on statin therapy post-operatively had lower 12-month mortality compared to those not on statin therapy (7.7% vs 30.0%, p=.028). Major amputation rate at 12 months was lower among patients prescribed antiplatelet therapy immediately post-operatively (6.3% vs 40%, p=.008) with effect maintained at 1 year (5.8% vs 28.6% p=.033).

Table 1 [Tab. 1], Figure 1 [Fig. 1]

Conclusion: DUS graft surveillance programmes can represent a vital opportunity to adequately optimise statin and antiplatelet therapy post-revascularisation in order to reduce the 12-month major amputation and mortality rates.


Conte MS, Bradbury AW, Kolh P, White JV, Dick F, Fitridge R, Mills JL, Ricco JB, Suresh KR, Murad MH, Aboyans V, Aksoy M, Alexandrescu VA, Armstrong D, Azuma N, Belch J, Bergoeing M, Bjorck M, Chakfé N, Cheng S, Dawson J, Debus ES, Dueck A, Duval S, Eckstein HH, Ferraresi R, Gambhir R, Gargiulo M, Geraghty P, Goode S, Gray B, Guo W, Gupta PC, Hinchliffe R, Jetty P, Komori K, Lavery L, Liang W, Lookstein R, Menard M, Misra S, Miyata T, Moneta G, Munoa Prado JA, Munoz A, Paolini JE, Patel M, Pomposelli F, Powell R, Robless P, Rogers L, Schanzer A, Schneider P, Taylor S, De Ceniga MV, Veller M, Vermassen F, Wang J, Wang S; GVG Writing Group for the Joint Guidelines of the Society for Vascular Surgery (SVS), European Society for Vascular Surgery (ESVS), and World Federation of Vascular Societies (WFVS). Global Vascular Guidelines on the Management of Chronic Limb-Threatening Ischemia. Eur J Vasc Endovasc Surg. 2019 Jul;58(1S):S1-S109.e33. DOI: 10.1016/j.ejvs.2019.05 Externer Link
NHS England. Summary of National Guidance for Lipid Management for Primary and Secondary Prevention of CVD. 2020 [Retrieved 15 September 2021]. Available from: Externer Link